• Keine Ergebnisse gefunden

Effect of Wnt5a on drug resistance in estrogen receptor-positive breast cancer Ai Amioka

N/A
N/A
Info
Herunterladen
Protected

Academic year: 2022

Aktie "Effect of Wnt5a on drug resistance in estrogen receptor-positive breast cancer Ai Amioka"

Copied!
2
0
0

Wird geladen.... (Jetzt Volltext ansehen)

Jetzt herunterladen ( 2 Seite )

Volltext

(1)

Effect of Wnt5a on drug resistance in estrogen receptor-positive breast cancer

Ai Amioka1), Takayuki Kadoya1), Satoshi Sueoka1), Yoshie Kobayashi1), Shinsuke Sasada1), Akiko Emi1), Norio Masumoto1), Masaoki Ito1), Koh Nakayama2), Morihito Okada1)

1) Department of Surgical Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, 1-2-3 Kasumi, Minami-Ku, Hiroshima 734-8551, Japan

2) Oxygen Biology Laboratory, Medical Research Institute, Tokyo Medical and Dental University, Bunkyo-ku, Tokyo 113-8510, Japan

Corresponding author：

Takayuki Kadoya, M.D, Ph.D

Email: takayukikadoya@gmail.com Tel.: +81-082-257-5869

Fax: +81-082-256-7109

(2)

Online Resource 3

Postoperative treatment of recurrent cases of ER-positive breast cancer

Cases Wnt5a expression Adjuvant

chemotherapy

Adjuvant hormone therapy

1 positive − TAM

2 positive − TAM, LH-RHa

3 positive − AI

4 positive TC AI

5 positive FEC+DTX −

6 negative TC AI

Abbreviations: TAM, Tamoxifen; LH-RHa, Luteinizing hormone-releasing hormone agonist; AI, Aromatase inhibitor; TC, Docetaxel + Cyclophosphamide; FEC, 5- Fluorouracil + Epirubicin + Cyclophosphamide; DTX, Docetaxel.

Referenzen

Jetzt herunterladen ( PDF - 2 Seite - 84.12 KB )

ÄHNLICHE DOKUMENTE

Effect of Wnt5a on drug resistance in estrogen receptor‑positive breast cancer

Wnt5a is thus potentially involved in the poor prognosis of ER-positive breast cancer independently of the PI3K–AKT–mTOR signaling pathway.. Keywords Wnt5a ·

Effect of Wnt5a on drug resistance in estrogen receptor-positive breast cancer Ai Amioka

[r]

Effect of Wnt5a on drug resistance in estrogen receptor-positive breast cancer Ai Amioka

Twenty-four hours after Wnt5a-siRNA transfection, western blot was.. performed to confirm that Wnt5a was

receptor‑positive, human epidermal growth factor receptor 2‑negative breast cancer that progressed on endocrine therapy

To gain a better understanding of the efficacy and safety of abemaciclib in Japanese breast cancer patients, the current analysis examined the Japanese subpopulation of MONARCH 2,

SLC1A5 co‑expression with TALDO1 associates with endocrine therapy failure in estrogen receptor‑positive breast cancer

Consistent with our clinical findings, SLC1A5 knockdown resulted in increased sensitivity to tamoxifen in luminal breast cancer cells, suggesting that high SLC1A5 expression

Lost in Translation? Estrogen Receptor Status and Endocrine Responsiveness in Breast Cancer

23 Perhaps even in vivo assessment of endocrine responsiveness will be required to augment baseline assess- ment, such as was already implemented in the American College of

Poor Outcome in Estrogen Receptor ^ Positive Breast Cancers Predicted by Loss of Plexin B1

All 119 breast cancer samples were ranked according to their Affymetrix expression values of Plexin B1 (215807_s_at), ESR1 (205225_at), and their proliferative activity based on

Gene expression of topoisomerase II alpha (TOP2A) by microarray analysis is highly prognostic in estrogen receptor (ER) positive breast cancer

In conclusion, this large scale analysis of gene expres- sion data in ER positive breast cancer patients demonstrates a strong prognostic impact of TOP2A expression, outper-